Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 1, 2012, Pages 233-245

  Esbenshade, Timothy A ^a   Browman, Kaitlin E ^a   Miller, Thomas R ^a   Krueger, Kathleen M ^a   Komater Roderwald, Victoria ^a   Zhang, Min ^a   Fox, Gerard B ^a   Rueter, Lynne ^a   Robb, Holly M ^a   Radek, Richard J ^a   Drescher, Karla U ^a   Fey, Thomas A ^a   Bitner, R Scott ^a   Marsh, Kennan ^a   Polakowski, James S ^a   Zhao, Chen ^a   Cowart, Marlon D ^a   Hancock, Arthur A ^a   Sullivan, James P ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; ABT 288; ACETYLCHOLINE; DOPAMINE; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BINDING AFFINITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOPAMINE RELEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ELECTROENCEPHALOGRAM; HISTAMINE RELEASE; HUMAN; HYPERACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LEARNING; MALE; MAZE TEST; MEMORY; MOUSE; NEWBORN; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; REFERENCE MEMORY; SLOW BRAIN WAVE; SOCIAL RECOGNITION MEMORY; SPATIAL LEARNING;

ANIMALS; AVOIDANCE LEARNING; COGNITION; GUINEA PIGS; HEK293 CELLS; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MICE; NOOTROPIC AGENTS; PROTEIN BINDING; PYRIDAZINES; PYRROLES; RATS; RATS, INBRED SHR; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H3; RECOGNITION (PSYCHOLOGY);

EID: 84866327781     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194126     Document Type: Article

References (56)

1. Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, and Schwartz JC (1987) Highly potent and selective ligands for histamine H3 receptors. Nature 327:117-123. (Pubitemid 17062756)
2. Arrang JM, Garbarg M, and Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302:832-837. (Pubitemid 13125123)
3. Arrang JM, Garbarg M, and Schwartz JC (1985) Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 15:553-562. (Pubitemid 15002136)
4. Arrang JM, Morisset S, and Gbahou F (2007) Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 28:350-357.
5. Bakker RA, Timmerman H, and Leurs R (2002) Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 17:27-64.
6. Baldi E, Bucherelli C, Schunack W, Cenni G, Blandina P, and Passani MB (2005) The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat. Neuropharmacology 48:246-251. (Pubitemid 40208260)
7. Barnes JC, Brown JD, Clarke NP, Clapham J, Evans DJ, and O'Shaughnessy CT (1993) Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. Eur J Pharmacol 250:147-152. (Pubitemid 23353071)
8. Blandina P, Bacciottinin L, Giovannini M, and Mannaioni P (1998) H3 receptor modulation of the release of neurotransmitters in vivo, in The Histamine H3 Receptor (Leurs R and Timmerman H eds) pp 27-40, Elsevier, Amsterdam, The Netherlands.
9. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, Pepeu G, and Giovannini MG (1996) Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 119:1656-1664. (Pubitemid 27019542)
10. 3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 336:38-46.
11. Browman KE, Zhang M, Fox GB, and Rueter LE (2009) Schizophrenia, in The Third Histamine Receptor (Vohora D ed) pp 329-354, CRC Press, Boca Raton, FL.
12. Celanire S, Lebon F, and Stark H (2009) Drug discovery: from hits to clinical candidates, in The Third Histamine Receptor (Vohora D ed) pp 103-166, CRC Press, Boca Raton, FL.
13. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
14. 3 receptor subtypes. Br J Pharmacol 107:919-923.
15. Cowart MD, Zhao C, Black LA, Zheng GZ, Gregg RJ, Zhang GZ, Sheikh AY, Lou X, Henry RF, Barnes DM, et al. (2007) inventors; Abbott Laboratories, assignee. Octahydro-Pyrrolo[3,4-B] pyrrole derivatives and their use as histamine-3 receptor ligands. WO/2007/100990. 2007 July 9.
16. o. J Pharmacol Toxicol Methods 50:187-199.
17. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59:1-8.
18. 3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166-1181.
19. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6:77-88, 59.
20. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313:165-175. (Pubitemid 40411340)
21. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] : II Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313:176-190. (Pubitemid 40411341)
22. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131:151-161.
23. 3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 332:164-172.
24. Haas HL, Sergeeva OA, and Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183-1241.
25. Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59:415-419.
26. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
27. 3 receptors. Eur J Pharmacol 433:141-150.
28. 3 receptor antagonists in two models of spatial learning. Behav Brain Res 159:295-300.
29. Le S, Gruner JA, Mathiasen JR, Marino MJ, and Schaffhauser H (2008) Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 325:902-909. (Pubitemid 351724342)
30. Leff P and Dougall IG (1993) Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14:110-112. (Pubitemid 23113114)
31. Leurs R, Vischer HF, Wijtmans M, and de Esch IJ (2011) En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 32:250-257.
32. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, et al. (2007a) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 73:1215-1224.
33. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, and Schwartz J (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658-666. (Pubitemid 29133666)
34. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, et al. (2007b) BF2.649 (1-{3-(3-(4-chlorophenyl)propoxy)propyl}piperidine, hydrochloride), a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320:365-375. (Pubitemid 46025751)
35. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, and Erlander MG (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55:1101-1107. (Pubitemid 29252378)
36. 3) visualized in the brain of human and non-human primates. Brain Res 526:322-327.
37. 3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321:1032-1045.
38. 3 receptor antagonists. Br J Pharmacol 157:139-149.
39. 3 receptors regulates histamine neurons in brain. Nature 408:860-864.
40. Passani MB, Blandina P, Browman KE and Fox GB (2009) Cognition functions, attention deficit hyperactivity disorders, and Alzhemier's disease, in The Third Histamine Receptor (Vohora D ed) pp 213-240, CRC Press, Boca Raton, FL.
41. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25:618-625.
42. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 3rd ed, Academic Press, San Diego.
43. Pepeu G and Giovannini MG (2004) Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem 11:21-27. (Pubitemid 38167054)
44. Pinkham AE, Penn DL, Perkins DO, and Lieberman J (2003) Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry 160:815-824. (Pubitemid 41079565)
45. Polakowski JS, King AJ, Campbell TJ, Nelson RA, Preusser LC, Kempf-Grote AJ, Marsh KC, Gintant GA, Cox BF, and Mittelstadt SW (2009) Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. J Cardiovasc Pharmacol 54:543-551.
46. Prast H, Argyriou A, and Philippu A (1996) Histaminergic neurons facilitate social memory in rats. Brain Res 734:316-318. (Pubitemid 26334060)
47. 3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther 340:124-133.
48. Schild HO (1947) pA2, a new scale for the measurement of drug antagonism. Br J Pharmacol Chemother 2:189-206.
49. 3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 337:588-590.
50. Schlicker E, Fink K, Detzner M, and Göthert M (1993) Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 93:1-10. (Pubitemid 23235613)
51. Schlicker E, Fink K, Hinterthaner M, and Göthert M (1989) Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch Pharmacol 340:633-638. (Pubitemid 20023150)
52. 3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163:713-721.
53. 3 receptor antagonist GSK207040. Psychopharmacology 201:483-494.
54. Strakhova M and Esbenshade TA (2007) Characterization of histaminergic receptors. Curr Protoc Pharmacol 37:1.19.1-1.19.24.
55. 3 receptor antagonists, in two functional models. Eur J Pharmacol 351:307-311.
56. Winslow JT and Camacho F (1995) Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology (Berl) 121:164-172.